Katie Rolfe

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

Thomas Voit, Haluk Topaloğlu, Volker Straub et al. · The Lancet Neurology · 2014 · 293 citations

Placebo-controlled Phase 2, Medicine, Duchenne Muscular Dystrophy +5

Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency

Maria Pia Cicalese, Francesca Ferrua, Laura Castagnaro et al. · Blood · 2016 · 212 citations · Full text

Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease

К. Ray Chaudhuri, Pablo Martínez‐Martín, Katie Rolfe et al. · European Journal of Neurology · 2011 · 103 citations

Investigating variability in patient response to treatment – a case study from a replicate cross-over study

Stephen Senn, Katie Rolfe, Steven A. Julious · Statistical Methods in Medical Research · 2010 · 77 citations

Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety

Maria Pia Cicalese, Francesca Ferrua, Laura Castagnaro et al. · Molecular Therapy · 2018 · 59 citations · Full text